11
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      Are you tired of sifting through news that doesn't interest you?
      Personalize your Karger newsletter today and get only the news that matters to you!

      Sign up

      • Record: found
      • Abstract: found
      • Article: found

      Pili Torti as a Sign of Eyebrow Involvement in Frontal Fibrosing Alopecia

      case-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Frontal fibrosing alopecia (FFA) is a disease characterized by progressive band-like scarring alopecia involving the frontotemporal hairline and eyebrow hair loss. It affects mainly postmenopausal women. Trichoscopy features of FFA include absence of vellus hair, perifollicular erythema and scaling (peri­pilar casts), and absence of follicular openings. Trichoscopy of eyebrows in FFA patients shows tapered and broken hair, absence of follicular openings, black dots, and hair growing in different directions. We report a case of FFA with numerous pili torti in the eyebrows.

          Related collections

          Most cited references8

          • Record: found
          • Abstract: found
          • Article: not found

          Frontal fibrosing alopecia: a multicenter review of 355 patients.

          To our knowledge, there are no large multicenter studies concerning frontal fibrosing alopecia (FFA) that could give clues about its pathogenesis and best treatment.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Frontal Fibrosing Alopecia: An Update on Pathogenesis, Diagnosis, and Treatment.

            Frontal fibrosing alopecia (FFA), first described by Kossard in the early 1990s, is a form of primary lymphocytic cicatricial alopecia characterized by selective involvement of the frontotemporal hairline and eyebrows. Since the original description, an increasing number of cases have been reported worldwide and the clinical aspects of the disease have been better characterized. However, the pathogenesis is still unknown and several hypotheses have been made about possible triggering factors, including hormones, neurogenic inflammation, smoking, UV filters, and ingredients in leave-on facial products. A genetic basis has also been hypothesized as the disease can occur in siblings and members of the same family. Besides its pathogenesis, research is also focused on treatment; FFA is a chronic condition and at present there is no validated or approved treatment for this disorder. Commonly prescribed topical treatments include corticosteroids, minoxidil, and calcineurin inhibitors. Systemic treatments include 5α-reductase inhibitors, hydroxychloroquine, and retinoids. Intralesional triamcinolone acetonide is also utilized, especially for the eyebrows. Other possible treatments include pioglitazone, naltrexone, tofacitinib, and lasers.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Scalp dermoscopy or trichoscopy.

              Scalp dermoscopy or `trichoscopy' represents a valuable, noninvasive technique for the evaluation of patients with hair loss that allows for magnified visualization of the hair and scalp skin. It may be performed with a manual dermoscope (×10 magnification) or a videodermoscope (up to ×1,000 magnification). In particular, trichoscopy enhances the diagnosis of androgenetic alopecia, alopecia areata, telogen effluvium, trichotillomania, congenital triangular alopecia, scarring alopecia, tinea capitis and hair shaft disorders. This method is simple, quick and easy to perform, reduces the need for scalp biopsy, is well accepted by patients, and is useful for monitoring treatment and follow-up.
                Bookmark

                Author and article information

                Journal
                SAD
                SAD
                10.1159/issn.2296-9160
                Skin Appendage Disorders
                S. Karger AG
                2296-9195
                2296-9160
                2019
                November 2019
                29 August 2019
                : 5
                : 6
                : 393-395
                Affiliations
                [_a] aDermatology Service, Hospital Ramos Mejía, Universidad de Buenos Aires, Buenos Aires, Argentina
                [_b] bDepartment of Dermatology, University of Bologna, Bologna, Italy
                [_c] cDr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA
                Author notes
                *Bruno Ferrari, Dermatology Service, Hospital Ramos Mejía, Urquiza 609, Buenos Aires, CABA C1221ADC (Argentina), E-Mail brunoferraripiel@gmail.com
                Article
                502059 PMC6883447 Skin Appendage Disord 2019;5:393–395
                10.1159/000502059
                PMC6883447
                31799271
                450e5c7c-6a94-4f15-8a7a-f65d33ce7662
                © 2019 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                : 25 May 2019
                : 11 July 2019
                Page count
                Figures: 2, Pages: 3
                Categories
                Novel Insights from Clinical Practice

                Oncology & Radiotherapy,Pathology,Surgery,Dermatology,Pharmacology & Pharmaceutical medicine
                Pili torti,Frontal fibrosing alopecia,Alopecia

                Comments

                Comment on this article